News
EQS-News: STRATEC TO PARTICIPATE IN THE 41ST ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
EQS-News: STRATEC TO PARTICIPATE IN THE 41ST ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
GenSight Biologics Announces Publication of Indirect Comparison of LUMEVOQ® Versus Natural History in ND4-LHON Patients in Peer-Reviewed Journal Ophthalmology and Therapy
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221214006010/en/
Figure 1: from Indirect Comparison of Lenadogene
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
EQS-Adhoc: PAION AG convenes extraordinary general meeting for capital reductions by redemption and consolidation of shares
EQS-Adhoc: PAION AG convenes extraordinary general meeting for capital reductions by redemption and consolidation of shares
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Dexcom Canada Partners With Green Shield and The Health Depot to Offer Plan Members a Comprehensive Digital Diabetes Care Experience
Dexcom, Inc. (NASDAQ: DXCM), a leader in real-time continuous glucose monitoring (rtCGM), announced today its partnership with Green Shield and The Health Depot digital pharmacy to provide Green
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
EQS-News: MorphoSys Presents New Longer-term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity, at ASH 2022
EQS-News: MorphoSys Presents New Longer-term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity, at ASH 2022
EQS-News: MorphoSys Presents Updated Tafasitamab Results in Newly Diagnosed DLBCL Patients from Final firstMIND Analysis at ASH 2022
EQS-News: MorphoSys Presents Updated Tafasitamab Results in Newly Diagnosed DLBCL Patients from Final firstMIND Analysis at ASH 2022
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
EQS-News: Carl Zeiss Meditec remains on growth course in fiscal year 2021/22
EQS-News: Carl Zeiss Meditec remains on growth course in fiscal year 2021/22
Dexcom G7 Receives FDA Clearance: The Most Accurate Continuous Glucose Monitoring System Cleared in the U.S.
DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the FDA has cleared the next-generation Dexcom G7 Continuous
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
EQS-News: Biotest AG: First patient enrolled in phase II clinical trial for treatment of chronic hepatitis B with hyperimmunoglobulins
EQS-News: Biotest AG: First patient enrolled in phase II clinical trial for treatment of chronic hepatitis B with hyperimmunoglobulins
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
EQS-News: MorphoSys Out Licenses Pre-Clinical Oncology Program
EQS-News: MorphoSys Out Licenses Pre-Clinical Oncology Program
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
EQS-News: Gerresheimer AG: Gerresheimer to expand significantly in High Value Solutions and further accelerates its sustainable profitable growth
EQS-News: Gerresheimer AG: Gerresheimer to expand significantly in High Value Solutions and further accelerates its sustainable profitable growth
EQS-Adhoc: Helen Giza is the new CEO of Fresenius Medical Care; Dr. Carla Kriwet leaves the company
EQS-Adhoc: Helen Giza is the new CEO of Fresenius Medical Care; Dr. Carla Kriwet leaves the company
EQS-News: Fresenius Medical Care AG & Co. KGaA: Helen Giza to take over as Chief Executive Officer of Fresenius Medical Care
EQS-News: Fresenius Medical Care AG & Co. KGaA: Helen Giza to take over as Chief Executive Officer of Fresenius Medical Care
EQS-Adhoc: Fresenius Medical Care AG & Co. KGaA: Ms. Helen Giza appointed as new CEO of the Management Board; Dr. Carla Kriwet agreed to resign as CEO and member of the Management Board
EQS-Adhoc: Fresenius Medical Care AG & Co. KGaA: Ms. Helen Giza appointed as new CEO of the Management Board; Dr. Carla Kriwet agreed to resign as CEO and member of the Management Board
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
EQS-News: NEW APPOINTMENT TO BOARD OF MANAGEMENT OF STRATEC SE
EQS-News: NEW APPOINTMENT TO BOARD OF MANAGEMENT OF STRATEC SE